Photodynamic Diagnosis for Superficial Bladder Cancer: Do All Risk-Groups Profit Equally from Oncological and Economic Long-Term Results?
Clinical medicine. Oncology · 2009
DOI: 10.4137/cmo.s1012 ↗At a glance
Journal article in Clinical medicine. Oncology, 2009. Written by Wolfgang Otto and 7 co-authors. Institution: Department of Urology, University of Regensburg, Germany. Cited 2 times so far (Crossref); 28 references. The full text is freely available in PubMed Central.
Abstract (original language)
Objective
Photodynamic diagnosis (PDD) of superficial bladder cancer decreases recurrence rates. We present oncological results of a randomized, prospective study, comparing transurethral resection (TUR) performed under conventional white light (WL) with PDD. The follow-up period is the longest reported to date. As costs might be reimbursed by prolonged recurrence-free survival in certain patients cost analysis in regard to risk-groups was performed. Material and methods Using chi-square test and log-rank test we compared recurrence rates of 103 patients after WL-TUR and of 88 patients after PDD-TUR. Cost analysis was performed according to risk-groups of recurrence.
Results
Mean follow-up was 99 months. Recurrence rate was 57% in WL vs. 28% in PDD (p < 0.001). Costs incurred by subsequent TUR averaged € 2310 per WL patient vs. € 713 per PDD patient. Savings per patient by PDD amounted to € 1597. PDD costs were reimbursed in low, intermediate and high risk patients, respectively.
Conclusions
PDD-TUR is significantly superior to conventional WL-TUR in terms of recurrence rate. While economic benefit is most prominent in intermediate risk patients, PDD related costs are reimbursed in all risk-groups.
Subjects
Author keywords
Authors and institutions
- Department of Urology, University of Regensburg, Germany.
Cite
APA
Otto, W., Burger, M., Fritsche, H. M., Blana, A., Roessler, W., Knuechel, R., Wieland, W. F., & Denzinger, S. (2009). Photodynamic Diagnosis for Superficial Bladder Cancer: Do All Risk-Groups Profit Equally from Oncological and Economic Long-Term Results?. Clinical medicine. Oncology. https://doi.org/10.4137/cmo.s1012
Vancouver
Otto W, Burger M, Fritsche HM, Blana A, Roessler W, Knuechel R, et al. Photodynamic Diagnosis for Superficial Bladder Cancer: Do All Risk-Groups Profit Equally from Oncological and Economic Long-Term Results?. Clinical medicine. Oncology. 2009. doi:10.4137/cmo.s1012
BibTeX
@article{Otto2009,
author = {Otto, Wolfgang and Burger, Maximilian and Fritsche, Hans-Martin and Blana, Andreas and Roessler, Wolfgang and Knuechel, Ruth and Wieland, Wolf F and Denzinger, Stefan},
title = {Photodynamic Diagnosis for Superficial Bladder Cancer: Do All Risk-Groups Profit Equally from Oncological and Economic Long-Term Results?},
journal = {Clinical medicine. Oncology},
year = {2009},
doi = {10.4137/cmo.s1012}
}
EUVIMED